ClinicalTrials.gg
Status unknownNCT03804541Updated Jan 15, 2019

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

A Phase 1 interventional study of Ensartinib in ALK-POSITIVE NSCLC, sponsored by Betta Pharmaceuticals Co., Ltd.. Status unknown at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-15.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects. The study will be conducted into two steps:Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the completion date of plasma, urine and feces sampling on the 3rd day post-dose and onwards. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 4-6 subjects will be adjusted according to the pilot study.

Read the detailed description

Subjects who had signed informed consent and meet inclusion criteria and no exclusion criteria are admitted to Phase I Clinical Unit two days prior to dosing (D-2). On the morning of Day 1 before dosing, subjects will be transferred to nuclear medical ward. And after an overnight fast of at least 10 h, subjects will receive a single oral dose of 200 mg (100 μCi) of [14C]Ensartinib as an oral suspension. Then, after two days of the dosing, subjects will be transferred back to Phase I Clinical Unit ward and confined to this unit until blood or excreta sampling and safety monitoring at the designated time points or intervals are complete

02

Conditions studied

  • ALK-POSITIVE NSCLC
03

In context

Lead sponsor

Betta Pharmaceuticals Co., Ltd. is the lead sponsor of 79 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for study participation if he meets the following criteria:

  1. healthy male volunteers between the ages of 18 to 50 years old, inclusive;
  2. Body weight >=50 kg, (body weight(kg)/hight2(m2)) between 19 and 26 kg/m2 (inclusive);
  3. Normal physical findings, clinical laboratory values, vital signs and 12-lead , or any abnormality that is non-;
  4. Male subjects of with partners will be instructed to, and must be willing to practice a highly effective method of for the duration of the study and continuing 1 year after discontinuing treatment with the product. Highly effective methods of birth control include using condom, contraceptive sponge, contraceptive gel, contraceptive film, intrauterine device, oral or injectable contraceptive pill, hypodermic implants or others;
  5. Must understand, and voluntarily sign the , comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for study participation if he meets any of the exclusion criteria:

  1. History of or current cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;
  2. Positive test for , HBeAg, anti-, anti- or syphilis antibody;
  3. History of clinically significant disease or infection within 1 month before entering the study;
  4. Abnormality in blood pressure, including hypertensive BP (SBP>=140 mmHg, or DBP >=90 mmHg), or hypotensive BP(SBP\<90 mmHg, or DBP \<=55 mmHg), Pulse rate\<55 bpm or >100 bpm;
  5. Long- syndrome or family history of it, or QTcB interval > 450 ms; intraventricular blocks or left/right bundle branch block or QRS>120ms; frequent ventricular ectopic beats (any 10s ventricular premature beat >= 1 in screening period); or abnormal resting heart rate (> 100 bpm)
  6. The following abnormal clinical laboratory values

    1. HGB \< LLN, and is judged as clinically significant by the investigator;
    2. Abnormal ALP, ALB,TP,CRE,,AST,BIL,BUN, GLU value, and is judged as clinically significant by the investigator;
  7. Received any drug within 14 days before taking the drug, including any prescription drug, OTC drug or herbal drug, except for vitamins and paracetamol;
  8. History of or current swallowing disorder, active gastrointestinal diseases, or other diseases that significantly affect absorption, distribution, metabolism and excretion of drugs;
  9. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease;
  10. Hemorrhoids or perianal disease with regular/perianal bleeding;
  11. Allergies, have allergies to two or more drugs or foods; or have known allergies to the components of the drug (microcrystalline cellulose, stearic acid, hydroxypropyl methylcellulose);
  12. Have donated 500ml or more of blood or plasma 2 months prior to the study drug administration, or more than 50ml within 2 weeks prior to administration;
  13. Vaccination was administered within 6 months prior to screening or during screening;
  14. History of drug or alcohol abuse;
  15. Smoking (> 10 cigarette / day), drinking (> 15 g, pure alcohol / day, equivalent to 450 ml beer, 150 ml wine or 50 ml low-alcohol liquor), or abusing drugs(MOP, METmAMP, MTD, THC, AMP positive) within last 3 months;
  16. Subject with mentally ill and could not understand the property, scope and possible consequences of the study;
  17. subject in prison or whose freedom is restricted by administrative or legal issues;
  18. Failure to comply with clinical study protocols, such as non-cooperation, follow-up visit and completion of entire study;
  19. Investigator, pharmacist, CRC or research associate;
  20. Investigators think that subjects are not suitable to participate in the study;
  21. Subjects who have participated in radiolabeled clinical study prior to drug administration;
  22. Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    [14C]Ensartinib

    To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of \[14C\]Ensartinib to healthy Chinese male subjects。

    Drug: Ensartinib

Interventions

  • A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.

    Also known as: X-396

06

What researchers measure

Primary outcomes

  1. Radioactivity concentration of each plasma sample

    Use liquid scintillation counter to evaluate Radioactivity concentration of each plasma(DPM/ml) sample

    Time frame: Day1-Day15

  2. Radioactivity concentration of each urine samples

    Use liquid scintillation counter to evaluate Radioactivity concentration of each urine(DPM/ml) sample

    Time frame: Day1-Day15

  3. Radioactivity concentration of each feces sample

    Use liquid scintillation counter to evaluate Radioactivity concentration of each feces(DPM/g) sample

    Time frame: Day1-Day15

  4. Total recovery of radioactivity in urine and feces

    Calculate the total radioactivity in urine and feces based on the radioactivity concentration of each sample.

    Time frame: Day1-Day15

Secondary outcomes

  1. Plasma drug concentrations

    To determine the plasma concentrations of Ensartinib with validated LC-MS/MS method for obtaining its pharmacokinetics parameters;

    Time frame: Day1-Day15

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    According to CTCAE v4.03, the number and frequency of adverse events after a single dose of test drug were assessed.

    Time frame: Day1-Day15

07

Study locations

1 of 1 sites recruiting
  • Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine
    Nanjing, Jiangsu Provence 210005, China
    Recruiting
08

References and documents

Publications

  • Nijenhuis CM, Schellens JH, Beijnen JH. Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metab Rev. 2016 May;48(2):266-80. doi: 10.1080/03602532.2016.1181081. Epub 2016 May 17. PubMed 27186889 ↗
  • Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 2009 May;30(4):185-203. doi: 10.1002/bdd.661. PubMed 19544285 ↗
  • Zhou S, Liu W, Zhou C, Zhang L, Xie L, Xu Z, Wang L, Zhao Y, Guo L, Chen J, Ding L, Mao L, Tao Y, Zhang C, Ding S, Shao F. Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer Chemother Pharmacol. 2020 Dec;86(6):719-730. doi: 10.1007/s00280-020-04159-0. Epub 2020 Oct 12. PubMed 33044566 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Jun 2019, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2018
First posted
Jan 15, 2019
StartActual
Dec 28, 2018
Primary completionEst.
Jun 2019
CompletionEst.
Oct 2019
Last update
Jan 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03804541
Responsible party
Sponsor
First posted
Jan 15, 2019
Start date
Dec 28, 2018
Primary completion
Jun 2019 (estimated)
Completion
Oct 2019 (estimated)
Last update
Jan 15, 2019

Study contacts

Feng Shao
Contact
shaofengnj@163.com
+8613851691161
Sufeng Zhou
Contact
zhousfhappy@163.com
+8615952052032
Feng Shao
principal investigator · Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensartinib

Start the discussion